JPMorgan Downgrades Pharmacyclics (PCYC) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500, Dow futures dip as big banks' earnings roll in ahead of CPI data; IBM slides
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
Pharmacyclics (PCYC) Remains Rated Sector Perform at RBC, PT Raised to $145
February 19, 2015 9:04 AM ESTRBC Capital maintained a Sector Perform rating on Pharmacyclics (NASDAQ: PCYC) and raised its price target to $145.00 (from $130.00). Comments follow Q4 results. Analyst Michael J. Yee thinks bulls are in control of the stock.
"We predict stock likely to keep trending up... More
Nomura Securities Upgrades Pharmacyclics (PCYC) to Buy
February 19, 2015 6:59 AM ESTNomura Securities upgraded Pharmacyclics (NASDAQ: PCYC) from Neutral to Buy with a price target of $196.00 (from $195.00), saying the RESONATE-2 data is key to upside in 2015
Analyst M. Ian Somaiya commented, "Pharmacyclics management reaffirmed their 2015 US sales guidance of $1bn and more importantly confirmed results of... More
UPDATE: Roth Capital Cuts Pharmacyclics (PCYC) to Neutral; Sees FY15 Guidance, Market Expectations Priced into Shares
February 19, 2015 6:56 AM EST(Updated - February 19, 2015 8:59 AM EST)
Roth Capital cuts Pharmacyclics (Nasdaq: PCYC) from Buy to Neutral and moves its price target from $189 to $187 following FY14 results reported on Wednesday night.
After markets close, Pharmacyclics posted Q4 EPS of $0.96 on revs of $290... More
Pharmacyclics (PCYC) Tops Q4 EPS by 20c
February 18, 2015 4:02 PM ESTPharmacyclics (NASDAQ: PCYC) reported Q4 EPS of $0.96, $0.20 better than the analyst estimate of $0.76. Revenue for the quarter came in at $290 million versus the consensus estimate of $267.5 million.
Worldwide Collaboration and License Agreement with Janssen
Under the Agreement, the repayment of... More
